Esperion Therapeutics Inc. (ESPR) Receives $19.91 Average Target Price from Analysts
Esperion Therapeutics Inc. (NASDAQ:ESPR) has been assigned an average rating of “Hold” from the thirteen research firms that are presently covering the firm. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $19.91.
A number of research firms recently weighed in on ESPR. JMP Securities reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Sunday, November 6th. Vetr raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and set a $12.60 target price for the company in a research note on Monday, August 8th. Chardan Capital reissued a “neutral” rating and issued a $12.50 target price on shares of Esperion Therapeutics in a research note on Saturday, October 15th. Zacks Investment Research cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 30th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $30.00 target price (down from $64.00) on shares of Esperion Therapeutics in a research note on Saturday, October 15th.
In related news, COO Narendra D. Lalwani acquired 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 1st. The stock was acquired at an average cost of $9.93 per share, with a total value of $49,650.00. Following the completion of the purchase, the chief operating officer now directly owns 5,000 shares in the company, valued at $49,650. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 35.40% of the company’s stock.
Large investors have recently made changes to their positions in the company. BlackRock Advisors LLC boosted its stake in shares of Esperion Therapeutics by 14.7% in the third quarter. BlackRock Advisors LLC now owns 7,419 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 951 shares during the period. Quantitative Investment Management LLC bought a new stake in shares of Esperion Therapeutics during the second quarter worth approximately $111,000. Advisor Group Inc. bought a new stake in shares of Esperion Therapeutics during the second quarter worth approximately $140,000. Stifel Financial Corp boosted its stake in shares of Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 1,438 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Esperion Therapeutics during the third quarter worth approximately $157,000. 65.29% of the stock is owned by institutional investors and hedge funds.
Shares of Esperion Therapeutics (NASDAQ:ESPR) opened at 11.76 on Wednesday. Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $30.41. The stock’s market capitalization is $265.22 million. The company has a 50-day moving average price of $11.53 and a 200 day moving average price of $12.65.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.82) by $0.05. During the same period last year, the firm earned ($0.57) EPS. Analysts forecast that Esperion Therapeutics will post ($3.42) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Esperion Therapeutics Inc. (ESPR) Receives $19.91 Average Target Price from Analysts” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and reposted in violation of US & international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/26/esperion-therapeutics-inc-espr-receives-19-91-average-target-price-from-analysts.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.